Harashima SI - Search Results

1

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.

Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. Sorli C, et al. Among authors: harashima si. Lancet Diabetes Endocrinol. 2017 Apr;5(4):251-260. doi: 10.1016/S2213-8587(17)30013-X. Epub 2017 Jan 17. Lancet Diabetes Endocrinol. 2017. PMID: 28110911 Clinical Trial.

2

Effects of structured testing versus routine testing of blood glucose in diabetes self-management: A randomized controlled trial.

Nishimura A, Harashima SI, Fujita Y, Tanaka D, Wang Y, Liu Y, Inagaki N. Nishimura A, et al. Among authors: harashima si. J Diabetes Complications. 2017 Jan;31(1):228-233. doi: 10.1016/j.jdiacomp.2016.08.019. Epub 2016 Aug 28. J Diabetes Complications. 2017. PMID: 27653670 Free article. Clinical Trial.

3

Color record in self-monitoring of blood glucose improves glycemic control by better self-management.

Nishimura A, Harashima S, Honda I, Shimizu Y, Harada N, Nagashima K, Hamasaki A, Hosoda K, Inagaki N. Nishimura A, et al. Diabetes Technol Ther. 2014 Jul;16(7):447-53. doi: 10.1089/dia.2013.0301. Epub 2014 Feb 7. Diabetes Technol Ther. 2014. PMID: 24506479 Free article. Clinical Trial.

4

Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post-hoc analysis.

Araki E, Harashima S, Nishida T, Nakamura J. Araki E, et al. J Diabetes Investig. 2022 Dec;13(12):1971-1980. doi: 10.1111/jdi.13905. Epub 2022 Oct 12. J Diabetes Investig. 2022. PMID: 36222597 Free PMC article.

5

Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus.

Inagaki N, Harashima SI, Kaku K, Kondo K, Maruyama N, Otsuka M, Kawaguchi Y, Iijima H. Inagaki N, et al. Among authors: harashima si. Diabetes Obes Metab. 2018 Apr;20(4):812-820. doi: 10.1111/dom.13152. Epub 2017 Dec 5. Diabetes Obes Metab. 2018. PMID: 29110384 Free PMC article. Clinical Trial.

6

Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.

Inagaki N, Harashima S, Maruyama N, Kawaguchi Y, Goda M, Iijima H. Inagaki N, et al. Cardiovasc Diabetol. 2016 Jun 18;15:89. doi: 10.1186/s12933-016-0407-4. Cardiovasc Diabetol. 2016. PMID: 27316668 Free PMC article. Clinical Trial.

7

Once Daily Self-Monitoring of Blood Glucose (SMBG) Improves Glycemic Control in Oral Hypoglycemic Agents (OHA)-Treated Diabetes: SMBG-OHA Follow-Up Study.

Harashima S, Nishimura A, Ikeda K, Wang Y, Liu Y, Inagaki N. Harashima S, et al. J Diabetes Sci Technol. 2015 Oct 1;10(2):378-82. doi: 10.1177/1932296815608869. J Diabetes Sci Technol. 2015. PMID: 26428934 Free PMC article.

8

Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.

Harashima SI, Inagaki N, Kondo K, Maruyama N, Otsuka M, Kawaguchi Y, Watanabe Y. Harashima SI, et al. Diabetes Obes Metab. 2018 Jul;20(7):1770-1775. doi: 10.1111/dom.13267. Epub 2018 Mar 24. Diabetes Obes Metab. 2018. PMID: 29473709 Free PMC article. Clinical Trial.

9

Self-monitoring of blood glucose (SMBG) improves glycaemic control in oral hypoglycaemic agent (OHA)-treated type 2 diabetes (SMBG-OHA study).

Harashima S, Fukushima T, Sasaki M, Nishi Y, Fujimoto S, Ogura M, Yamane S, Tanaka D, Harada N, Hamasaki A, Nagashima K, Nakahigashi Y, Seino Y, Inagaki N. Harashima S, et al. Diabetes Metab Res Rev. 2013 Jan;29(1):77-84. doi: 10.1002/dmrr.2363. Diabetes Metab Res Rev. 2013. PMID: 23008090 Clinical Trial.

10

Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients.

Inagaki N, Harashima SI, Iijima H. Inagaki N, et al. Among authors: harashima si. Expert Opin Pharmacother. 2018 Jun;19(8):895-908. doi: 10.1080/14656566.2018.1473378. Epub 2018 May 25. Expert Opin Pharmacother. 2018. PMID: 29799286

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

75 results

Search Page